| REVIEW ARTICLE |
|
| Year : 2017 | Volume
: 7
| Issue : 2 | Page : 62-69 |
|
|
Pharmacological therapy for amblyopia
Anupam Singh, Ritu Nagpal, Sanjeev Kumar Mittal, Chirag Bahuguna, Prashant Kumar
Department of Ophthalmology, All Institute of Medical Sciences, Rishikesh, Uttarakhand, India
Correspondence Address:
Anupam Singh
Department of Ophthalmology, All India Institute of Medical Sciences, Rishikesh - 249 203, Uttarakhand
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/tjo.tjo_8_17
|
|
|
Amblyopia is the most common cause of preventable blindness in children and young adults. Most of the amblyopic visual loss is reversible if detected and treated at appropriate time. It affects 1.0 to 5.0% of the general population. Various treatment modalities have been tried like refractive correction, patching (both full time and part time), penalization and pharmacological therapy. Refractive correction alone improves visual acuity in one third of patients with anisometropic amblyopia. Various drugs have also been tried of which carbidopa & levodopa have been popular. Most of these agents are still in experimental stage, though levodopa-carbidopa combination therapy has been widely studied in human amblyopes with good outcomes. Levodopa therapy may be considered in cases with residual amblyopia, although occlusion therapy remains the initial treatment choice. Regression of effect after stoppage of therapy remains a concern. Further studies are therefore needed to evaluate the full efficacy and side effect profile of these agents. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
